ArticleBMC public health2026
Estimating hypertension medication adherence among adults using linked Belgian health interview survey and administrative pharmacy refill data.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication adherence includes initiation, implementation, and persistence. Population-level estimates are commonly based on administrative claims, yet these may not fully capture patient behavior. This study developed a framework to estimate adherence to antihypertensive treatment using linked self-reported data and medication refill records from a representative Belgian sample.
methodsWe linked participants of the 2018 Belgian Health Interview Survey (BHIS) with Belgian Compulsory Health Insurance (BCHI) records via pseudonymized identifiers. Chronic hypertension patients were defined as those with at least one antihypertensive prescription in the year prior to the study and ≥ 30 consecutive days of treatment during the study year. Adherence was assessed using three approaches: (1) regimen-level Proportion of Days Covered in 2018 (PDCY) capturing implementation and persistence; (2) Proportion of Days Covered in a flexible period (PDCF) capturing implementation during persistence; and (3) BHIS-based self-reported medication use at the interview date cross-validated with prescriptions. We also calculated Medication Possession Ratios (MPR) for drug class–specific adherence. Agreement between methods was tested with Cohen’s Kappa and McNemar’s test; predictors of adherence were analyzed using logistic regression.
resultsOf 2,475 chronic hypertension patients (22.6% of BHIS sample; mean age 67.1 years, 52.8% female), adherence rates were similar across indicators (PDCY: 58.3%; PDCF: 57.1%; BHIS: 61.4%). Kappa values indicated fair, consistent agreement, while McNemar’s test showed no systematic differences between methods. Logistic models identified age, multimorbidity, and polypharmacy as significant predictors of adherence, with effect sizes varying by measurement approach.
conclusionsFindings suggest that short-term adherence measured via self-report provides a reasonable proxy for long-term adherence. Linking survey and administrative data offers a robust and practical alternative to claims-only approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.